Denosumab for joints and bones
- 68 Downloads
Denosumab is an investigational, fully human monoclonal antibody with a high affinity and specificity for receptor activator of nuclear factor κ B ligand (RANKL), a cytokine member of the tumor necrosis factor family. RANKL, an essential mediator of osteoclast formation, function, and survival, plays a major role in the pathogenesis of postmenopausal osteoporosis, structural damage in rheumatoid arthritis, and bone loss associated with other skeletal disorders. Denosumab suppresses bone turnover by inhibiting the action of RANKL on osteoclasts. Denosumab reduces bone turnover and increases bone mineral density in postmenopausal women with low bone mineral density, reduces fracture risk in women with postmenopausal osteoporosis, and inhibits structural damage in patients with rheumatoid arthritis when added to ongoing methotrexate treatment. It is generally well tolerated, with a good safety profile. Adverse and serious adverse events, including infections and malignancy, are similar in patients treated with denosumab or placebo.
Unable to display preview. Download preview PDF.
References and Recommended Reading
- 2.US Department of Health and Human Services: Bone Health and Osteoporosis: A Report of the Surgeon General. Rockville, MD: US Department of Health and Human Services, Office of the Surgeon General; 2004.Google Scholar
- 4.International Osteoporosis Foundation: IOF Osteoporosis Teaching Slide Kit. Available at http://www.osteofound.org/health_professionals/teaching_resources/slide_kit.html. Accessed March 2006.
- 16.Peterson MC, Stouch BJ, Martin SW, et al.: The pharmacokinetics of denosumab (AMG 162) following various multiple subcutaneous dosing regimens in postmenopausal women with low bone mass. J Bone Miner Res 2005, 20(Suppl 1):S293.Google Scholar
- 19.Miller PD, Bolognese MA, Lewiecki EM, et al.: Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone 2008, 43:222–229.PubMedCrossRefGoogle Scholar
- 21.Brown JP, Prince RL, Deal C, et al.: Comparison of the effect of denosumab and alendronate on bone mineral density and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res 2009, 24:153–161.PubMedCrossRefGoogle Scholar
- 22.Kendler DL, Benhamou CL, Brown JP, et al.: Effects of denosumab vs alendronate on bone mineral density (BMD), bone turnover markers (BTM), and safety in women previously treated with alendronate. J Bone Miner Res 2008, S473.Google Scholar
- 23.Cummings SR, McClung MR, Christiansen C, et al.: A phase III study of the effects of denosumab on vertebral, nonvertebral, and hip fracture in women with osteoporosis: results from the FREEDOM trial. J Bone Miner Res 2008, 23(Suppl 1):S80.Google Scholar
- 24.Amgen Inc: Form 8-K. Available at http://investors.amgen.com/phoenix.zhtml?c=61656&p=irol-sec. Accessed September 2008.
- 25.Cohen SB, Dore RK, Lane NE, et al.: Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum 2008, 58:1299–1309.PubMedCrossRefGoogle Scholar
- 29.Cohen SB, Lewiecki EM, Liu Y, et al.: Phase 2 study of denosumab (AMG 162) in postmenopausal women: subanalyses and supplemental safety. J Bone Miner Res 2005, 20(Suppl 1):S295.Google Scholar